[go: up one dir, main page]

MA50899B1 - Composés utiles pour l'inhibition de cdk7 - Google Patents

Composés utiles pour l'inhibition de cdk7

Info

Publication number
MA50899B1
MA50899B1 MA50899A MA50899A MA50899B1 MA 50899 B1 MA50899 B1 MA 50899B1 MA 50899 A MA50899 A MA 50899A MA 50899 A MA50899 A MA 50899A MA 50899 B1 MA50899 B1 MA 50899B1
Authority
MA
Morocco
Prior art keywords
compounds useful
cdk7 inhibition
cdk7
inhibition
novel
Prior art date
Application number
MA50899A
Other languages
English (en)
Other versions
MA50899A (fr
Inventor
David Andrew Coates
David Michael Remick
Carlos Montero
Bharvin Kumar Rameschandra Patel
Vipin Yadav
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Priority claimed from PCT/US2018/060025 external-priority patent/WO2019099298A1/fr
Publication of MA50899A publication Critical patent/MA50899A/fr
Publication of MA50899B1 publication Critical patent/MA50899B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne de nouveaux inhibiteurs de cdk7 et des compositions pharmaceutiques associées : (i), ou un sel pharmaceutiquement acceptable de ceux-ci.
MA50899A 2017-11-16 2018-11-09 Composés utiles pour l'inhibition de cdk7 MA50899B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17382778 2017-11-16
PCT/US2018/060025 WO2019099298A1 (fr) 2017-11-16 2018-11-09 Composés utiles pour l'inhibition de cdk7

Publications (2)

Publication Number Publication Date
MA50899A MA50899A (fr) 2020-09-23
MA50899B1 true MA50899B1 (fr) 2022-10-31

Family

ID=60484312

Family Applications (1)

Application Number Title Priority Date Filing Date
MA50899A MA50899B1 (fr) 2017-11-16 2018-11-09 Composés utiles pour l'inhibition de cdk7

Country Status (2)

Country Link
AR (1) AR113817A1 (fr)
MA (1) MA50899B1 (fr)

Also Published As

Publication number Publication date
MA50899A (fr) 2020-09-23
AR113817A1 (es) 2020-06-17

Similar Documents

Publication Publication Date Title
JOP20200122B1 (ar) مركبات مفيدة لتثبيط cdk7
MA43169B1 (fr) Composés héterocycliques en tant qu' inhibiteurs pi3k-gamma
GEP20237561B (en) Protein tyrosine phosphatase inhibitors
GEP20237506B (en) Pcsk9 antagonist compounds
EA201691401A1 (ru) Индазольные соединения в качестве ингибиторов irak4
MA42339A1 (fr) Modulateurs du récepteur farnésoïde x
MA51204B1 (fr) Formes pharmaceutiques comprenant un inhibiteur de la kallicréine plasmatique
EA201991884A3 (ru) Ингибиторы g12c kras
MA46337A (fr) Composé de pyridine
JOP20190233A1 (ar) نظائر بنزوازيبين بوصفها عوامل مثبطة لتيروزين كيناز بروتون
MA42776B1 (fr) Composés utiles pour l'inhibition du ror-gamma-t
EA202193015A1 (ru) Ингибиторы cdk
MX2020001531A (es) Nuevos compuestos hetorociclicos como inhibidores de cdk8/19.
EA201992542A1 (ru) Фармацевтическая композиция для местного применения, содержащая, по меньшей мере, амитриптилин, для лечения периферической нейропатической боли
MA39335B1 (fr) Inhibiteurs mgat2 de dihydropyridinone à substitution tétrazolone
MX2019001781A (es) Compuestos de tiofeno condensado utiles como inhibidores de napi-iib.
MX2018001979A (es) (s,e) -3- (6-aminopiridin-3-il) -n- ( (5- (4- (3-fluoruro-3 metilpirrolidin-1-carbonil) fenil) -7- (4 fluorofenil) benzofuran-2-il)metil)acrilamida para el tratamiento del cancer.
MA43052B1 (fr) Inhibiteurs de la kallicréine plasmatique humaine
MA43913B1 (fr) Modulateurs allostériques positifs du récepteur m1 muscarinique
PH12021550258A1 (en) Cdk8/19 inhibitors
MA46039B1 (fr) Dérivé de triazolopyrazinone utile en tant qu'inhibiteur de pde1 humain
EA202190339A1 (ru) Пиридопиримидины в качестве ингибиторов н4-гистаминовых рецепторов
MA50899B1 (fr) Composés utiles pour l'inhibition de cdk7
EP2862573A4 (fr) Composition pour le traitement ou la prévention de maladies causées par une perméabilité vasculaire, contenant de l'imatinib ou un sel pharmaceutiquement acceptable de celui-ci en tant que principe actif
MA44383B1 (fr) Un derivé de 4-(3-pyrazolylamino)-benzimidazole en tant qu'inhibiteur de jak1 pour le traitement du cancer